Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 19 years or older, of any gender
- People who have been diagnosed with multiple myeloma and have already been treated with at least three specific types of therapy: a proteasome inhibitor, an immunomodulatory drug, and a monoclonal antibody (one from each category)
- People whose multiple myeloma has returned or stopped responding to treatment, with this diagnosis made between the trial's approval date and December 2025, and for whom a doctor has scheduled the start of a new immunotherapy treatment within one month of the initial screening
- People who have been fully informed about the study and have voluntarily agreed in writing to take part and follow the study's requirements
Who may not be able to join:
- People who do not agree to take part in the study
- People diagnosed with a plasma cell disorder other than multiple myeloma, such as lymphoma or POEMS syndrome
- People who are unable to read and understand documents written in Korean
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-10-3782-2736
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Quality of Lfe
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.